Pharmacokinetics, Amino Acid Responses, and Short-Term Tolerability of Intravenous and Oral L-Citrulline in Healthy Neonatal Holstein Calves.

IF 1.4 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY
Mehmet Gültekin, Murat Boyacıoğlu, Hasan Erdoğan, Kerem Ural, Hüseyin Voyvoda, Gamze Gültekin, Gizem Gönülveren, Onur Yılmazer, Ece Eylül Sönmez
{"title":"Pharmacokinetics, Amino Acid Responses, and Short-Term Tolerability of Intravenous and Oral L-Citrulline in Healthy Neonatal Holstein Calves.","authors":"Mehmet Gültekin, Murat Boyacıoğlu, Hasan Erdoğan, Kerem Ural, Hüseyin Voyvoda, Gamze Gültekin, Gizem Gönülveren, Onur Yılmazer, Ece Eylül Sönmez","doi":"10.1111/jvp.70101","DOIUrl":null,"url":null,"abstract":"<p><p>L-citrulline is a precursor for endogenous arginine synthesis, supporting nitric oxide production and urea cycle function, yet its pharmacokinetics in neonatal calves are unknown. This study characterized and compared the pharmacokinetics of L-citrulline after intravenous (IV) and oral (PO) administration in healthy neonatal Holstein calves and evaluated associated amino acid responses and short-term clinical and laboratory tolerability. Six healthy male calves (2-4 weeks old) received a single 150 mg/kg dose of L-citrulline as extemporaneously prepared 5% (w/v) IV and 10% (w/v) PO formulations in a randomized 2-period crossover design with a 7-day washout. Blood samples were collected pre-dose and up to 48 h post-dose. Plasma amino acids were quantified by LC-MS/MS, and pharmacokinetic parameters were estimated using non-compartmental analysis. After IV administration, the highest observed total plasma L-citrulline concentration was detected at the first post-dose sampling time, 5 min after bolus administration (C<sub>peak</sub> 2213 ± 629 μmol/L; range, 1329-2830 μmol/L). After PO administration, C<sub>max</sub> was 1107 ± 371 μmol/L (range, 623-1478 μmol/L), with a median T<sub>max</sub> of 60 min (range, 45-120 min). Baseline-corrected non-compartmental analysis yielded t<sub>1/2</sub> values of 2.32 ± 0.79 h after IV administration and 2.23 ± 0.60 h after PO administration, with AUC<sub>0-∞</sub> values of 4130 ± 558 and 3444 ± 1067 μmol·h/L, respectively. Absolute oral bioavailability was 0.86 ± 0.32 (range, 0.52-1.28). Both routes increased plasma arginine (max +159% IV; +122% PO) and ornithine (max +132% IV; +149% PO) with no clinically relevant adverse effects or laboratory abnormalities during short-term monitoring of clinical, hematological, biochemical, blood gas/electrolyte, and coagulation variables. These findings support further evaluation of L-citrulline as a nutritional and/or therapeutic supplement in neonatal calves.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of veterinary pharmacology and therapeutics","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/jvp.70101","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

L-citrulline is a precursor for endogenous arginine synthesis, supporting nitric oxide production and urea cycle function, yet its pharmacokinetics in neonatal calves are unknown. This study characterized and compared the pharmacokinetics of L-citrulline after intravenous (IV) and oral (PO) administration in healthy neonatal Holstein calves and evaluated associated amino acid responses and short-term clinical and laboratory tolerability. Six healthy male calves (2-4 weeks old) received a single 150 mg/kg dose of L-citrulline as extemporaneously prepared 5% (w/v) IV and 10% (w/v) PO formulations in a randomized 2-period crossover design with a 7-day washout. Blood samples were collected pre-dose and up to 48 h post-dose. Plasma amino acids were quantified by LC-MS/MS, and pharmacokinetic parameters were estimated using non-compartmental analysis. After IV administration, the highest observed total plasma L-citrulline concentration was detected at the first post-dose sampling time, 5 min after bolus administration (Cpeak 2213 ± 629 μmol/L; range, 1329-2830 μmol/L). After PO administration, Cmax was 1107 ± 371 μmol/L (range, 623-1478 μmol/L), with a median Tmax of 60 min (range, 45-120 min). Baseline-corrected non-compartmental analysis yielded t1/2 values of 2.32 ± 0.79 h after IV administration and 2.23 ± 0.60 h after PO administration, with AUC0-∞ values of 4130 ± 558 and 3444 ± 1067 μmol·h/L, respectively. Absolute oral bioavailability was 0.86 ± 0.32 (range, 0.52-1.28). Both routes increased plasma arginine (max +159% IV; +122% PO) and ornithine (max +132% IV; +149% PO) with no clinically relevant adverse effects or laboratory abnormalities during short-term monitoring of clinical, hematological, biochemical, blood gas/electrolyte, and coagulation variables. These findings support further evaluation of L-citrulline as a nutritional and/or therapeutic supplement in neonatal calves.

健康新生荷斯坦犊牛静脉注射和口服l -瓜氨酸的药代动力学、氨基酸反应和短期耐受性
l -瓜氨酸是内源性精氨酸合成的前体,支持一氧化氮的产生和尿素循环功能,但其在新生牛犊中的药代动力学尚不清楚。本研究描述并比较了l -瓜氨酸在健康新生荷斯坦犊牛静脉注射(IV)和口服(PO)后的药代动力学,并评估了相关的氨基酸反应和短期临床和实验室耐受性。6头健康雄性犊牛(2-4周龄)接受单剂量150 mg/kg的l -瓜氨酸临时配制5% (w/v) IV和10% (w/v) PO配方,随机2期交叉设计,7天洗脱期。在给药前和给药后48小时采集血样。采用LC-MS/MS定量测定血浆氨基酸,采用非区室分析估计药代动力学参数。静脉给药后,在给药后第一次采样时间,即给药后5 min,血浆总L-瓜氨酸浓度最高(峰值2213±629 μmol/L,范围1329 ~ 2830 μmol/L)。给药后Cmax为1107±371 μmol/L(范围623 ~ 1478 μmol/L),中位Tmax为60 min(范围45 ~ 120 min)。经基线校正的非区室分析,IV给药后t1/2值为2.32±0.79 h, PO给药后t1/2值为2.23±0.60 h, AUC0-∞值分别为4130±558和3444±1067 μmol·h/L。绝对口服生物利用度为0.86±0.32(范围0.52-1.28)。在临床、血液学、生化、血气/电解质和凝血变量的短期监测中,两种途径均增加血浆精氨酸(静脉注射最多+159%,静脉注射最多+122%)和鸟氨酸(静脉注射最多+132%,静脉注射最多+149%),无临床相关不良反应或实验室异常。这些发现支持进一步评估l -瓜氨酸作为新生儿犊牛营养和/或治疗补充。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
15.40%
发文量
69
审稿时长
8-16 weeks
期刊介绍: The Journal of Veterinary Pharmacology and Therapeutics (JVPT) is an international journal devoted to the publication of scientific papers in the basic and clinical aspects of veterinary pharmacology and toxicology, whether the study is in vitro, in vivo, ex vivo or in silico. The Journal is a forum for recent scientific information and developments in the discipline of veterinary pharmacology, including toxicology and therapeutics. Studies that are entirely in vitro will not be considered within the scope of JVPT unless the study has direct relevance to the use of the drug (including toxicants and feed additives) in veterinary species, or that it can be clearly demonstrated that a similar outcome would be expected in vivo. These studies should consider approved or widely used veterinary drugs and/or drugs with broad applicability to veterinary species.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书